ライフサイエンスコーパス: solid organ

1 tructures and bystander blood vessels within solid organs.

2 to the building of more complex tissues and solid organs.

3 port cells surrounding microvessels found in solid organs.

4 se that was already established in secondary solid organs.

5 nsities and reduces the tumour burden within solid organs 10-fold.

6 neral population, some aspects are unique to solid organ allograft recipients.

7 mphoid tissue, but how their presence within solid organ allografts affects transplant outcomes is no

8 ance" is more favorable for liver than other solid organ allografts.

9 splant recipients of concomitantly recovered solid organ allografts.

10 After transplantation of nonrenal solid organs, an acute decline in kidney function develo

11 Solid organ and allogeneic hematopoietic cell transplant

12 nclude strong T-cell and B-cell responses to solid organ and cellular xenografts.

13 mains an important opportunistic pathogen in solid organ and hematopoietic cell transplantation, part

14 -mediated lymphoablation is commonly used in solid organ and hematopoietic cell transplantation.

15 nificant cause of morbidity and mortality in solid organ and hematopoietic stem cell transplant (HSCT

16 selected an update on infectious diseases in solid organ and hematopoietic stem cell transplantation.

17 ection and graft-versus-host disease in both solid organ and hematopoietic stem cell transplantation.

18 to those that occur with transplantation of solid organs and allogeneic hematopoietic stem cells (HS

19 maged by significant induction among diverse solid organs and circulation in peripheral blood, thereb

20 ied to the clinic for the transplantation of solid organs and in the treatment of human cancers respe

21 term outcomes of the concomitantly recovered solid organs and their recipients.

22 Outside the field of solid-organ and allogeneic HSC transplantation, new stra

23 of the key unmet needs in the fields of both solid-organ and hematopoietic stem cell transplant (HCT)

24 articularly in the congenital setting and in solid-organ and hematopoietic stem cell transplant patie

25 ies with lymphoproliferation and early-onset solid-organ autoimmunity associated with 9 different ger

26 Transplantation of solid organs between genetically distinct individuals le

27 alysis of the family overrule of donation of solid organs by deceased patients, and examine arguments

28 ed risk of posttransplant skin cancer, PTLD, solid organ cancer, death and graft failure.

29 Surgery plays a central role in therapy for solid organ cancer.

30 logy and Chronic Health Evaluation II score, solid-organ cancer, cirrhosis, and transfer from an outs

31 Recent studies in solid organ cancers have shown that cancer stem cells (C

32 ) developed 73 nonskin cancers, including 46 solid-organ cancers (renal, 11; colorectal, 11; prostate

33 ry T (T reg) cells in opposing and promoting solid organ carcinogenesis, respectively, is viewed as a

34 on Network database from 2000 to 2012 of all solid organ donors.

35 be a relevant therapeutic target to prevent solid organ dysfunction after injury.

36 red S. epidermidis infections from blood and solid organs, even when the animals were immunocompromis

37 ansplanting young adults and the shortage of solid organs for transplant, future studies are critical

38 ost and donor blood cells, guarantees that a solid organ from the same donor will be tolerated withou

39 fied the population of subjects who received solid organs from these 10 donors using the Scientific R

40 ation has been associated with more risk for solid organ graft rejection.

41 s that mesenchymal stromal cells can prolong solid organ graft survival and that they can induce immu

42 ntly associated with rejection of allogeneic solid organ grafts, regulatory T (T(reg)) cells appear t

43 eminating phenotype) such as bones and other solid organs, including brain.

44 ore regulators of fibroblast activity across solid organs, including the kidneys.

45 ar whether ischemic preconditioning (IPC) of solid organs induces remote IPC (RIPC) in donors after b

46 Forty-six solid organ injuries were identified in 38 patients by C

47 There were 17 unidentified solid organ injuries, and eight patients had active blee

48 Antibody-mediated rejection (AMR) of most solid organs is characterized by evidence of complement

49 tion outcomes of the concomitantly recovered solid organs is limited to isolated case reports and sho

50 1), skin (SHR, 1.55, 95% CI, 1.23-1.93), and solid organ malignancies (SHR, 1.54; 95% CI, 1.13-2.11).

51 therapy for breast cancer and numerous other solid organ malignancies, organ transplant, and immune s

52 ing has become the standard for staging most solid organ malignancies.

53 findings are combined with the presence of a solid organ mass, lymphoma should be included in the dif

54 Solid organ neoplasms are uncommon among patients with D

55 man immunodeficiency virus or AIDS, or prior solid organ or bone marrow transplantation with receipt

56 A total of 960 recipients of solid organ or bone marrow transplants were identified f

57 t require immunosuppressive therapies and/or solid organ or stem cell transplants.

58 y bowel disease, dermatologic conditions, or solid-organ or bone marrow transplantation.

59 including pregnant women, neutropenic hosts, solid-organ or stem cell transplant recipients, and pati

60 chronic renal failure, rheumatoid arthritis, solid-organ or stem-cell transplantation, and healthy co

61 Six hundred forty solid organ pancreas transplants were performed; 238 had

62 he outcomes of exercise training programs in solid organ recipients against standard care.

63 function assay shows promise for identifying solid organ recipients at risk for infection or rejectio

64 s extend and enhance the quality of life for solid organ recipients, and desensitization that permits

65 sion and could lead to improved outcomes for solid organ recipients.

66 We screened 263 solid-organ recipients for anti-HEV immunoglobulin G (Ig

67 dies (<7 WHO units/mL) seemed not to protect solid-organ recipients.

68 Little is known about anti-HEV immunity in solid-organ recipients.

69 creasingly the leading cause of mortality in solid-organ recipients.

70 allows sequestration of a kidney by another solid organ regardless of the priority of the candidate

71 he basis of tissue regeneration in mammalian solid organs remains undefined.

72 It is unclear how adult stem cells in solid organs respond to oncogenic stimulation and whethe

73 blood biomarkers, the transcriptional kidney Solid Organ Response Test (kSORT), and the IFN-gamma enz

74 A 17-gene set--the Kidney Solid Organ Response Test (kSORT)--was selected in 143 s

75 ality after hematopoietic stem cell (SCT) or solid organ (SOT) transplant.

76 allenges remain when addressing more complex solid organs such as the heart, liver, and kidney.

77 mewide for transplant outcomes that span all solid organs, such as graft survival, acute rejection, n

78 ayo Clinic who had bone marrow, fat pad, and solid organ tissue samples typed by liquid chromatograph

79 next-generation HSCT-mediated therapies for solid organ tolerance, cure of non-malignant hematologic

80 KP infections occurred more frequently among solid organ transplant (31%) and dialysis (17%) patients

81 lant failure or rejection (HR 3.2), previous solid organ transplant (HR 1.7), and several comorbiditi

82 Records of solid organ transplant (SOT) and hematopoietic cell tran

83 cal and molecular pretransplant screening in solid organ transplant (SOT) donors and recipients in no

84 Two groups were identified: the solid organ transplant (SOT) group (n = 15; 12 ITX and 3

85 s a potentially fatal disorder arising after solid organ transplant (SOT) or hematopoietic stem cell

86 Solid organ transplant (SOT) recipients are at elevated

87 Solid organ transplant (SOT) recipients are at risk of n

88 Approximately 3%-10% of solid organ transplant (SOT) recipients in CRE-endemic a

89 e of immune reconstitution syndrome (IRS) in solid organ transplant (SOT) recipients with cryptococco

90 ons have the potential to affect outcomes in solid organ transplant (SOT) recipients.

91 ug-resistant (XDR) Pseudomonas aeruginosa in solid organ transplant (SOT) recipients.

92 CMV) is an emerging and important problem in solid organ transplant (SOT) recipients.

93 utcomes associated with histoplasmosis after solid organ transplant (SOT), we report a large series o

94 Sepsis is a serious complication of solid organ transplant (SOT).

95 erculosis infection (LTBI) is recommended in solid organ transplant (SOT).

96 lity after hematopoietic stem cell (HSCT) or solid organ transplant (SOT).

97 n, affecting 0.04% to 3.5% of patients after solid organ transplant (SOT).

98 umoral rejection is the most common cause of solid organ transplant failure.

99 The charts of all patients receiving a solid organ transplant from 1990-2008 evaluated in the d

100 inimization and avoidance protocols for post-solid organ transplant have been developed.

101 ctious disease consultation in recipients of solid organ transplant is associated with increased LOS

102 Receiving a solid organ transplant owing to late-stage organ failure

103 sed by Nocardia thailandica in a 66-year-old solid organ transplant patient from Connecticut, which w

104 One hundred and fifty-three solid organ transplant patients were enrolled, including

105 Solid organ transplant patients with first episode of CM

106 (Carbapenem-Resistant Enterobacteriaceae in Solid Organ Transplant Patients) has provided pivotal da

107 In solid organ transplant patients, global suppression of i

108 with medication, could predict adherence in solid organ transplant patients.

109 emerged as a cause of persistent diarrhea in solid organ transplant patients.

110 romised individuals, such as bone marrow and solid organ transplant patients.

111 We reported 47 solid organ transplant recipients (41 kidneys) with cryp

112 reported an increased risk of skin cancer in solid organ transplant recipients (OTRs), no study has e

113 De novo solid organ transplant recipients (SOTR) have a steep le

114 Solid organ transplant recipients (SOTR) with a pretrans

115 enza vaccine effectiveness is not optimal in solid organ transplant recipients (SOTR).

116 or contributor to morbidity and mortality in solid organ transplant recipients (SOTRs).

117 e multiple risk factors for CNS processes in solid organ transplant recipients and establishes a time

118 Diabetes is prevalent among solid organ transplant recipients and is universal among

119 excess risk are similar to those observed in solid organ transplant recipients and patients with auto

120 Solid organ transplant recipients are at increased risk

121 as treatment of chronic hepatitis C virus in solid organ transplant recipients are limited.

122 n addition, a significant number of nonrenal solid organ transplant recipients develop chronic kidney

123 Another cluster of solid organ transplant recipients developed encephalitis

124 ssociated cluster of febrile illness among 3 solid organ transplant recipients from a common donor.

125 Solid organ transplant recipients have a high incidence

126 Solid organ transplant recipients have heightened risk f

127 Solid organ transplant recipients have increased risk fo

128 ecipients, which contains information on all solid organ transplant recipients in the United States,

129 eatment outcomes during CMV infection in 291 solid organ transplant recipients receiving valganciclov

130 ng Enterobacteriaceae and CRE carriage among solid organ transplant recipients to inform management o

131 cancer was assessed among 118,440 Caucasian solid organ transplant recipients using multivariate Cox

132 Solid organ transplant recipients were identified within

133 Non-lung solid organ transplant recipients who developed NSCLC ha

134 In solid organ transplant recipients who presented at our i

135 ates that elevated osteoprotegerin levels in solid organ transplant recipients with CMV infection may

136 view the current status of CMV resistance in solid organ transplant recipients, and provide diagnosti

137 In this study of 649 solid organ transplant recipients, followed prospectivel

138 erebral vasculature that occurs in 0.5-5% of solid organ transplant recipients, most commonly associa

139 hough diarrhea is a frequent complaint among solid organ transplant recipients, the contribution of i

140 tors for invasive mold infections among 1101 solid organ transplant recipients, thereby strengthening

141 Solid organ transplant recipients, who are medically imm

142 er phase II trial, 152 treatment-naive adult solid organ transplant recipients, with CD20(+) PTLD unr

143 iclovir for cytomegalovirus (CMV) disease in solid organ transplant recipients.

144 a major cause of graft loss and mortality in solid organ transplant recipients.

145 ing the incidence of rejection in HIV-to-HIV solid organ transplant recipients.

146 ysis over an 18-month period of hospitalized solid organ transplant recipients.

147 y of cases of antibody-mediated rejection in solid organ transplant recipients.

148 ients receiving immunosuppressing drugs, and solid organ transplant recipients.

149 infectious disease-related complications in solid organ transplant recipients.

150 stemic non-Hodgkin lymphoma (NHL) in 288 029 solid organ transplant recipients.

151 ting for chronic hepatitis in some pediatric solid organ transplant recipients.

152 endations are likely to be relevant to other solid organ transplant recipients.

153 ory affects posttransplantation mortality in solid organ transplant recipients.

154 on growth and safety parameters in pediatric solid organ transplant recipients.

155 l-based adjunct immunosuppressive therapy in solid organ transplant recipients.

156 ell recognized but uncommon complications in solid organ transplant recipients.

157 nd a leading cause of cancer mortality among solid organ transplant recipients.

158 Through linkage of the US solid organ transplant registry with 15 state/regional c

159 Co-management with a solid organ transplant specialist is helpful for the mon

160 partners, bridges research in the fields of solid organ transplant, hematopoietic cell transplant, a

161 event cytomegalovirus (CMV) infections after solid organ transplant.

162 s of primary cutaneous T-cell lymphoma after solid organ transplant.

163 he records of 59 patients who had received a solid-organ transplant (37 kidney-transplant recipients,

164 reatment of latent tuberculosis infection in solid-organ transplant (SOT) candidates.

165 ding bacteremia caused by these organisms in solid-organ transplant (SOT) recipients is lacking.

166 (IMI) among hematopoietic stem cell but not solid-organ transplant (SOT) recipients.

167 Thirty-five patients with a solid-organ transplant and chronic hepatitis E virus inf

168 omen of reproductive age who have received a solid-organ transplant are at risk for unplanned pregnan

169 this retrospective analysis of UNOS data for solid-organ transplant during a 25-year period (Septembe

170 ional markers aimed at identifying long-term solid-organ transplant patients at high risk of developi

171 been used to treat chronic HEV infection in solid-organ transplant patients with some success.

172 ating chronic hepatitis E virus infection in solid-organ transplant patients.

173 cies in ORF1 and the outcome of infection in solid-organ transplant patients.

174 six cases of PTLD were identified with 1392 solid-organ transplant recipient controls.

175 even patients (10 with HIV infection and one solid-organ transplant recipient) developed tuberculosis

176 life-years were saved (observed to date) per solid-organ transplant recipient.

177 umatoid arthritis (n = 199), 9.0 to 20.0% in solid-organ transplant recipients (n = 197), 0% to 5.8%

178 Solid-organ transplant recipients (OTRs) are at an incre

179 Immunosuppression (IS), such as in solid-organ transplant recipients (SOTRs) and patients w

180 Solid-organ transplant recipients (SOTRs) are at greater

181 0 fresh CMV DNA-positive plasma samples from solid-organ transplant recipients (SOTRs) were tested.

182 Solid-organ transplant recipients are at increased risk

183 A total of 840 solid-organ transplant recipients at risk for CMV infect

184 We describe four solid-organ transplant recipients with donor-derived Wes

185 the effects of ribavirin as monotherapy for solid-organ transplant recipients with prolonged HEV vir

186 fluence susceptibility to CMV replication in solid-organ transplant recipients, particularly in patie

187 onmelanoma skin cancer is well recognized in solid-organ transplant recipients, the risk of skin canc

188 implementation, which was not seen in other solid-organ transplant recipients.

189 idence of cytomegalovirus (CMV) infection in solid-organ transplant recipients.

190 ital charges among lung transplant and other solid-organ transplant recipients.

191 immunocompromised individuals, especially in solid-organ transplant recipients.

192 related outcomes across a range of different solid-organ transplant studies.

193 s) were saved to date during the 25 years of solid-organ transplant.

194 typically related to immunomodulation during solid-organ transplant.

195 Twenty-four solid-organ-transplant recipients with chronic hepatitis

196 Immune measurements that distinguish solid organ transplantation (SOT) recipients who control

197 dity and mortality among patients undergoing solid organ transplantation (SOT).

198 receptors, in regulating the alloresponse to solid organ transplantation (SOT).

199 ause of a complex diagnosis especially after solid organ transplantation and can lead to difficulties

200 nes on the prevention and treatment of TB in solid organ transplantation and hematopoietic stem cell

201 g the periocular region represents a risk of solid organ transplantation and may produce significant

202 description of a pathogenic role for NETs in solid organ transplantation and suggest that NETs are a

203 hematopoietic stem cell transplantation, or solid organ transplantation be screened for active or pr

204 A total of 3489 patients underwent solid organ transplantation between 1990 and 2008.

205 published with subject headings relating to solid organ transplantation between August 1, 2011, and

206 However, the number of patients awaiting solid organ transplantation continues to remain much hig

207 with PTLD or chronic high viral loads after solid organ transplantation exhibited no homogeneous EBV

208 nostic biomarkers of acute rejection (AR) in solid organ transplantation have been addressed in multi

209 of the oral cavity, which may develop after solid organ transplantation in children.

210 d in the National Institutes of Health (NIH) Solid Organ Transplantation in HIV Trial, reflecting exp

211 Solid organ transplantation is a curative therapy for hu

212 Solid organ transplantation is a vital therapy for end s

213 Acute kidney injury after nonrenal solid organ transplantation is associated with prolonged

214 Solid organ transplantation is encumbered by an increasi

215 Solid organ transplantation is the preferred treatment f

216 The field of solid organ transplantation is unique in the breadth of

217 Severe B-lineage PTLD after solid organ transplantation may be classified as SR or H

218 KIR haplotype B from viral replication after solid organ transplantation may extend beyond CMV to oth

219 In solid organ transplantation recipients, exercise is able

220 Solid organ transplantation reduces both morbidity and m

221 In most solid organ transplantation settings, the role of NK cel

222 Seventy-four cases of PTLD after solid organ transplantation with sufficient material for

223 d without hematologic malignancy or previous solid organ transplantation) that were collected for rou

224 most prevalent infectious complication after solid organ transplantation, and recipients of isolated

225 trials, including those for bone marrow and solid organ transplantation, autoimmune diseases, and ti

226 for treatment of cytomegalovirus disease in solid organ transplantation, confirmed genotypic drug re

227 he most common infectious complication after solid organ transplantation, frequently affecting the ga

228 After solid organ transplantation, immune-mediated rejection m

229 mains an important opportunistic pathogen in solid organ transplantation, particularly in lung transp

230 gical and infectious challenges accompanying solid organ transplantation, susceptibility to post-tran

231 Unlike solid organ transplantation, which is potentially life-s

232 l as after allogeneic hematopoietic cell and solid organ transplantation.

233 future is improving long-term outcomes after solid organ transplantation.

234 -mediated rejection and graft loss after all solid organ transplantation.

235 ty (APA) is recommended in patients awaiting solid organ transplantation.

236 challenge limiting allograft survival after solid organ transplantation.

237 volved in myocardial infarction, stroke, and solid organ transplantation.

238 The incidence of cancer is increased after solid organ transplantation.

239 y a significant role in graft survival after solid organ transplantation.

240 k of cytomegalovirus (CMV) replication after solid organ transplantation.

241 is an infrequent but serious complication of solid organ transplantation.

242 Diarrhea is a frequent complication of solid organ transplantation.

243 lograft survival is a major challenge facing solid organ transplantation.

244 ve drugs is one of the key research goals in solid organ transplantation.

245 f peanut allergy has been reported following solid organ transplantation.

246 of hematopoiesis and to induce tolerance for solid organ transplantation.

247 munocompromised patients, particularly after solid organ transplantation.

248 (HHV) and immune control of replication post-solid organ transplantation.

249 geographic variation in CMV management after solid organ transplantation.

250 nsplantation monitoring of HLA antibodies in solid organ transplantation.

251 oles in the cellular and humoral response in solid organ transplantation.

252 dressing the organ supply/demand mismatch in solid organ transplantation.

253 cluding those associated with bone marrow or solid organ transplantation.

254 ications of this novel MPS classification in solid organ transplantation.

255 s and outcomes associated with smoking after solid organ transplantation.

256 us 8 (HHV-8)-related disease described after solid organ transplantation.

257 infection is an ongoing clinical problem in solid-organ transplantation (SOT).

258 arity to oral calcineurin inhibitors used in solid-organ transplantation and spontaneous reporting of

259 Women with a history of solid-organ transplantation can be safely offered a wide

260 tic stem cell transplant cohort and excluded solid-organ transplantation from this cohort.

261 Current immunosuppression regimens for solid-organ transplantation have shown disappointing eff

262 based cohort study of patients who underwent solid-organ transplantation in Ontario, Canada, between

263 Cytomegalovirus (CMV) infection in solid-organ transplantation is associated with increased

264 promising strategy to induce tolerance after solid-organ transplantation or prevent graft-versus-host

265 and serum samples obtained from nonselected solid-organ transplantation patients suffering from prob

266 a, may support exclusion of pulmonary IFI in solid-organ transplantation patients, the low positive p

267 The SMR for cancer death after solid-organ transplantation was higher in children (SMR,

268 Solid-organ transplantation was identified using the nat

269 In the setting of solid-organ transplantation, calcineurin inhibitor (CNI)

270 lcohol and substance abuse in the context of solid-organ transplantation.

271 on systems have successfully been applied in solid organ transplantations.

272 ed all cryptosporidiosis cases identified in solid organ transplanted patients between 2006 and 2010

273 gained over the years shows that, similar to solid organ transplants (SOT), human VCA can also develo

274 apy for ESBL-producing Enterobacteriaceae in solid organ transplants and MCS device recipients are es

275 Outcomes after solid organ transplants are improving; for adult patient

276 The goals of tolerance in patients with solid organ transplants are to eliminate the lifelong ne

277 ded patients with end-stage renal disease or solid organ transplants because very few are uninsured.

278 Immunosuppressed patients with solid organ transplants have an increased risk for nonme

279 ent and Transplantation Network data, 28 051 solid organ transplants were performed in 2012.

280 inical trials to treat patients with cancer, solid organ transplants, and autoimmune diseases.

281 to induce rejection compared with most other solid organ transplants, and simultaneous transplantatio

282 g transplantation lags behind that for other solid organ transplants, primarily because of allograft

283 jection, which is in sharp contrast to other solid organ transplants, such as kidney, lung, and heart

284 ransplants and reduced long-term survival of solid organ transplants, we hypothesized that convention

285 the major obstacle for long-term survival of solid organ transplants.

286 n 2 million life-years were saved to date by solid-organ transplants during a 25-year study period.

287 how preexisting autoreactive T cells affect solid-organ transplants under these conditions is unknow

288 g transplantation is among the lowest of all solid-organ transplants, and current diagnostic tests of

289 ividuals with inflammatory bowel diseases or solid-organ transplants, virome dynamics in allogeneic h

290 h chronic hepatitis E who were recipients of solid-organ transplants.

291 een diagnosed with a hematologic malignancy, solid organ tumor, or who have other conditions that req

292 factor in breast cancer, melanoma, and other solid organ tumors with a lymphatic spread.

293 eath 1 (PD-1) antibodies in the treatment of solid-organ tumors, with an estimated frequency of 4.2%.

294 we assume a strong and generalized effect on solid organ viability by HOPE before transplantation.

295 stribution and trafficking of NK cells among solid organs, we have analyzed a wide array of tissues d

296 regulatory T (Treg) cells limit rejection of solid organs, we hypothesized that donor-reactive Treg i

297 A total of 36 solid organs were recovered and transplanted into 35 rec

298 ted once tumour cells affect the function of solid organs, with a high disease burden limiting effect

299 bowel lumen, wall, perienteric tissues, and solid organs within the abdomen.

300 enografts that may be applicable to clinical solid organ xenotransplantation.